Abstract
Background:
The rate of childhood cancer death has dropped steadily over the past 50 years. The pediatric cancer risk has remained under investigation.Objectives:
This study aims at investigating the associated factors with the survival of pediatric patients with retinoblastoma, sarcoma, brain tumor, and leukemia cancer.Methods:
The cohort study of 1879 children with retinoblastoma, sarcoma, brain tumor, and leukemia aged < 1, 1 - 5, 6 - 10, 11 - 15, and > 15 years in Mahak Hospital and Rehabilitation Complex from 2007 to 2016 were enrolled in the study. Median survival time was reported for each cancer. Parametric survival models including Gompertz, Weibull, lognormal, and log‑logistic models were fitted. Then, the model with almost minimum Akaike information criterion (AIC) was chosen. The hazard ratio (HR) and the analysis were performed by R3.5.1.Results:
Totally, 270 (14.37%) patients with retinoblastoma, 667 (35.5%) with leukemia, 625 (33.26%) with a brain tumor, and 317 (16.87%) with sarcoma were included in this study; 815 (43.37%) patients were female. Gompertz's model was chosen to fit the data due to the minimum AIC. The associated factors with the survival of childhood cancers were as follows: Age < 1 year, parental relation, loco-regional relapse and chemotherapy alone (HR: 7.63, 1.56, 4.61, 1.12) in leukemia, other nationalities, metastasis or metastasis and loco-regional relapse and chemotherapy alone (HR = 3.74, 5.75, 2.12) in retinoblastoma, loco-regional relapse and metastasis (HR = 2.40, 3.71) in brain tumor, other ages except for 5 - 10 years, parental relation, chemotherapy alone, and metastasis (HR = 33.3, 1.80, 3.57, 3.8) in sarcoma.Conclusions:
Age, parental familial relationships, combination therapy, and metastasis of primary cancer were the risk factors for survival of children with 4 common cancers of leukemia, retinoblastoma, brain tumors, and sarcoma, using the Gompertz model.Keywords
Cancer Childhood Parametric Survival Model Gompertz Model Retinoblastoma Sarcoma Brain Tumor Leukemia
1. Background
Cancer is a major worldwide public health problem and is considered the second leading death cause in children (1). The prevalence of pediatric cancer is estimated by the World Health Organization at approximately 100 per million children (2).
The incidence of this disease is higher in developed countries than in developing ones. According to 2012 statistics, approximately 19.3 per 100,000 children in East Africa suffer from pediatric cancer; however, 89.7 per 100,000 children in Western Europe suffer from pediatric cancer. Therefore, the incidence of this disease in developed societies other than Japan (more than 80 per 100,000 children) is higher than in developing societies (less than 40 per 100,000 children). But in recent years, the incidence of the disease has been increasing in developing countries (3).
The incidence of cancer among Iranian children varies in the geographical areas of the country; so, for girls and boys, it has been reported between 84 and 221 and 15 and 441 cases per million people, respectively (4).
The childhood cancer death rate has dropped steadily over the past 50 years. In about 80% of cancer cases in developed countries, where access to modern treatment and adequate supportive care is available, it can be successfully treated. However, only 10% of the world's children live in high-income countries, where there is extensive care (2).
Pediatric cancer accounts for 14.2 percent of the 23,300 deaths from cancer in Iranian children and makes it the number first cause of death rate (5).
Pediatric cancers are different from adult malignancies in terms of the type of cancer, the distribution, and the prognosis and they have a specific epidemiological pattern. Unlike adult cancers, most pediatric cancers are fatal without timely diagnosis and proper treatment. Also, there are no demographic screening programs or lifestyle risk reduction strategies that can be effective in improving pediatric cancer results (6).
Leukemia is the most common pediatric cancer, accounting for 28% of cases (including malignant tumors and borderline benign tumors), and brain tumors and the nervous system (about a quarter of which are malignant/borderline) account for 26% of cancers. Next, soft tissue sarcomas (7%), neuroblastoma (6%), non-Hodgkin's lymphomas, including, Burkitt's lymphoma (6%), kidney tumor (5%), and Hodgkin's lymphoma (3%) have their share in cancers (7, 8).
The pediatric cancer risk is increased due to genetic and prenatal factors (e.g., radiation, diethylstilbestrol) and postnatal factor (radiation, viruses), but in most pediatric cancer cases, the cause of cancer in children has remained unknown (9).
2. Objectives
This study aims at investigating the survival rate of pediatric cancer in demographic subgroups with different demographic, economic, social, and geographical conditions in Iran and comparing it with neighboring countries. In addition, the analysis was done, using parametric survival models. Then, a better fit was chosen as the final one.
3. Methods
This was a retrospective cohort study of 1879 children with a definitive diagnosis of cancer admitted at Mahak Hospital and Rehabilitation Center (a hospital affiliated with non-governmental organizations for cancer treatment). A data gathering form was firstly designed by researchers for data collection. The included variables were age, sex, nationality, consanguinity of parents, treatment type, and experience in follow-up.
3.1. Participants
In this investigation, 1879 patients had cancers of leukemia, retinoblastoma, brain cancer, and sarcoma from 2007 to 2016. All children with these cancers with available records were included in the study.
3.2. Variables
Patients were divided into Iranian and non-Iranian (Afghan, Iraqi, Azerbaijani, Kuwaiti, Bahrein, Emirati, and Pakistani) groups. Patient’s age was considered < 1, 1 - 5, 6 - 10, 11 - 15, and > 15 years.
Methods of treatment (chemotherapy, chemotherapy + surgery, chemotherapy + surgery + radiotherapy, and other combinations of these treatments) were taken into account. Experiences in follow-up included loco-regional relapse, metastasis, and other experiences such as the experience of loco-regional relapse and metastasis together were considered. The main outcome was time from diagnosis to death or the last follow-up.
3.3. Statistical Analysis
Continues and categorical clinical and demographic characteristics of the patients were reported in mean (standard deviation) and number (%), respectively. A chi-square test was used to compare the categorical characteristics of the patients between cancer groups. The median and interquartile range (IQR) survival time were reported. The effect of the nationality, age group (< 1, 1 - 5, 6 - 10, 11 - 15, > 15), sex, method of treatment (chemotherapy, chemotherapy + surgery, chemotherapy + surgery + radiotherapy, and other combinations of these treatments), consanguinity (parental relation) of patients, and experience in follow-up (loco-regional relapse, metastasis, and other such as second cancer or occurrence of metastasis and loco-regional relapse together) were assessed on survival. Parametric models including Gompertz, Weibull, lognormal, and log‑logistic models provided more accurate estimates if the correct shape was chosen. In this research, all the mentioned models were fitted after checking the corresponding assumptions (10). Models with minimum Akaike information criterion (AIC) were chosen for interpretations. A hazard ratio with a 95% confidence interval was reported. Significant effects in the univariable model (P < 0.2) were retained in the multiple models. However, clinically significant factors based on expert opinion were retained in the multiple models (11). The analysis was performed by R3.5.1. The significance level was set to 0.05.
3.4. Ethical Consideration
This study was approved by the regional Ethics Committee of the Shahid Beheshti University of Medical Sciences. The project code was IR.SBMU.RETECH.REC.1400.1033.
4. Results
A total of 1879 patients were included in the study as follows: 270 (14.37%) patients with retinoblastoma, 667 (35.5%) with leukemia cancer, 625 (33.26%) with a brain tumor, and 317 (16.87%) with sarcoma; 815 (43.37%) patients were female.
The median survival time (IQR) of the patients was 29.50 (6 - 70.5), 12 (6 - 46), 10 (5 - 45), and 17 (5 - 65) months for retinoblastoma, sarcoma, brain tumor, and leukemia, respectively. The number of deaths was 178 (26.7%) in leukemia patients, 37 (13.7%) in retinoblastoma patients, 174 (27.8%) in brain tumor patients, and 107 (33.8%) in sarcoma patients. Figure 1 shows the overall survival curve of the studied patients.
Kaplan-Meier curve of survival estimation adjusted for type of cancer (time in months)
Table 1 shows that patient’s age, type of treatment, and experiences in follow-up were significantly different between cancer types. Table 2 illustrates that the Gompertz model has almost the minimum AIC in comparison to the other models. Then, further assessments are performed based on this model and presented in Table 3.
Clinical and Demographic Characteristics of the Patients a
| Characteristics | Leukemia (n = 667) | Brain Tumor (n = 625) | Retinoblastoma (n = 270) | Sarcoma (n = 317) | P |
|---|---|---|---|---|---|
| Age years | < 0.001 b | ||||
| < 1 | 26 (3.9) | 37 (5.9) | 112 (41.5) | 13 (4.1) | |
| 1 - 5 | 314 (47.1) | 257 (41.1) | 150 (55.6) | 70 (22.1) | |
| 6 - 10 | 164 (24.6) | 209 (33.4) | 7 (2.6) | 96 (30.3) | |
| 11 - 15 | 143 (21.4) | 111 (17.8) | 0 | 121 (38.2) | |
| > 15 | 17 (2.5) | 7 (1.1) | 1 (0.4) | 15 (4.7) | |
| Nationality | 0.612 | ||||
| Iran | 611 (91.6) | 568 (90.9) | 242 (89.6) | 290 (91.5) | |
| Others | 55 (8.2) | 52 (8.3) | 28 (10.4) | 23 (7.3) | |
| Missing | 1 (0.1) | 5 (0.8) | 0 | 4 (1.3) | |
| Sex | 0.959 | ||||
| Male | 379 (56.8) | 357 (57.1) | 149 (55.2) | 179 (56.5) | |
| Female | 288 (43.2) | 268 (42.9) | 121 (44.8) | 138 (43.5) | |
| Parental relation | 0.040 | ||||
| No | 464 (69.6) | 393 (62.9) | 170 (63) | 202 (63.7) | |
| Yes | 152 (22.8) | 182 (29.1) | 78 (28.9) | 79 (24.9) | |
| Missing | 51 (7.6) | 50 (8) | 22 (8.1) | 36 (11.4) | |
| Treatment | < 0.001 b | ||||
| Chemotherapy chemo + radio | 556 (83.4) 92 (13.8) | 59 (9.4) 0 | 147 (54.4) 0 | 40 (12.6) 0 | |
| Chemo + surg | 0 | 178 (28.5) | 111 (41.1) | 153 (48.3) | |
| Chemo + surg + radio | 0 | 285 (45.6) | 8 (3) | 113 (35.6) | |
| Others | 14 (2.1) | 96 (15.4) | 0 | 10 (3.2) | |
| Missing | 5 (0.7) | 7 (1.1) | 4 (1.5) | 1 (0.3) | |
| Experience in follow-up | < 0.001 b | ||||
| None | 521 (78.1) | 537 (85.9) | 186 (68.9) | 225 (71) | |
| Loco-regional relapse | 134 (20.1) | 67 (10.7) | 76 (28.1) | 34 (10.7) | |
| Metastasis | 12 (1.8) | 17 (2.7) | 8 (3) | 37 (11.7) | |
| Other | 0 | 4 (0.6) | 0 | 21 (6.6) |
Akaike Information Criterion for Different Parametric Models in Each Type of Cancer
| Cancer Type | Models | |||
|---|---|---|---|---|
| Weibull (PH) | Gompertz (PH) | Lognormal (AFT) | Loglogistic | |
| Leukemia | 851.35 | 844.08 | 870.13 | 860.26 |
| Brain tumor | 870.20 | 846.21 | 836 | 838.01 |
| Retinoblastoma | 242.83 | 239.33 | 245.82 | 246.32 |
| Sarcoma | 425.13 | 425.51 | 427.34 | 428.60 |
The Hazard Ratio (95% CI) of the Factors on Patient’s Survival for Four Cancers Using the Gompertz Model
| Factors | Leukemia | P | Brain Tumor | P | Retinoblastoma | P | Sarcoma | P |
|---|---|---|---|---|---|---|---|---|
| Nationality | ||||||||
| Iran | ||||||||
| Others | 1.16 (0.60, 2.34) | 0.65 | 0.96 (0.46, 1.97) | 0.90 | 3.74 (1.38, 10.11) | 0.009 a | 0.81 (0.24, 2.75) | 0.73 |
| Age group (y) | ||||||||
| 1 - 5 | ||||||||
| < 1 | 7.63 (3.51, 16.60) | < 0.001 a | 0.78 (0.33, 1.87) | 0.58 | 1.06 (0.50, 2.26) | 0.88 | 1.02 (0.35, 2.99) | 0.97 |
| 6 - 10 | 1.25 (0.81, 1.92) | 0.31 | 1.11 (0.73, 1.68) | 0.63 | 1.42 (0.17, 11.75) | 0.74 | 0.30 (0.14, 0.63) | 0.001 a |
| 11 - 15 | 1.33 (0.87, 2.02) | 0.19 | 1.49 (0.93, 2.39) | 0.09 | - | - | 0.99 (0.58, 1.70) | 0.99 |
| > 15 | 1.37 (0.42, 4.45) | 0.60 | 2.15 (0.62, 7.47) | 0.23 | - | - | 0.69 (0.22, 2.13) | 0.52 |
| Sex (male) | 0.94 (0.66, 1.35) | 0.76 | 1.13 (0.79, 1.61) | 0.50 | 0.66 (0.32, 1.37) | 0.27 | 1.16 (0.74, 1.82) | 0.51 |
| Parental relation (yes) | 1.56 (1.08, 2.24) | 0.02 a | 1.18 (0.81, 1.73) | 0.39 | 1.42 (0.62, 3.27) | 0.40 | 1.80 (1.11, 2.92) | 0.02 a |
| treatment | ||||||||
| Chemo | ||||||||
| Chemo + radio | 0.89 (0.59, 1.36) | 0.60 | ||||||
| Chemo + surg | - | - | 1.07 (0.56, 2.05) | 0.83 | 0.47 (0.21, 1.02) | 0.06 | 0.36 (0.15, 0.89) | 0.03 a |
| Chemo + surg + radio | - | - | 0.64 (0.34, 1.22) | 0.18 | - | - | 0.28 (0.11, 0.69) | 0.006 a |
| Others | 0.56 (0.13, 2.33) | 0.42 | 1.28 (0.61, 2.65) | 0.51 | 0.60 (0.07, 4.63) | 0.62 | 0.38 (0.09, 1.64) | 0.19 |
| Experience in follow-up | ||||||||
| None | ||||||||
| Loco-regional relapse | 4.61 (3.20, 6.64) | < 0.001* *** | 2.40 (1.58, 3.64) | < 0.001 a | 1.34 (0.62, 2.89) | 0.45 | 1.00 (0.49, 2.07) | 0.99 |
| Metastasis | - | - | 3.71 (1.71, 8.06) | 0.001 a | - | - | 3.80 (2.16, 6.69) | < 0.001 a |
| Others | 0.98 (0.24, 4.08) | 0.98 | 2.62 (0.79, 8.70) | 0.11 | 5.75 (1.46, 22.72) | 0.01 a | 2.85 (1.51, 5.38) | 0.001 a |
4.1. Leukemia Patients
The patient with an age < 1 year had a mortality risk of 7.63 (3.51, 16.60) times more than the patients, who were 1 to 5 years (P < 0.001). The patients who had parental relations had a higher mortality hazard than the patients, who did not have parental relations (1.56 (1.08, 2.24), P = 0.02).
In addition, the patients with experience of loco-regional relapse had a mortality hazard of 4.61 (3.20, 6.64) times more than the patients, who did not experience relapse or metastasis as well as others during follow-up (P < 0.001), whereas the mortality hazard of the patient who had chemotherapy plus radiotherapy was lower than the patients who had chemotherapy alone (0.89 (0.59, 1.36), P = 0.60).
4.2. Retinoblastoma Patients
Mortality risk in other nationality patients was significantly higher than in Iranian patients (3.74 (1.38, 10.11), P = 0.009). The patients, who experienced metastasis or metastasis plus loco-regional relapse had a higher mortality risk than the patient who did not experience any particular conditions (5.75 (1.46, 22.72), P = 0.01). In addition, the patients, who were treated with both chemotherapy and surgery, had lower mortality than the patients, who were treated with chemotherapy (0.47 (0.21, 1.02), P = 0.06).
4.3. Brain Tumor Patients
The patients, who experienced recurrence during follow-up, had a significantly higher risk of death compared to the other patients (P < 0.001). The patients with the experience of either loco-regional relapse or metastasis had significantly higher mortality in comparison to those who experienced none of them (P = 0.001).
4.4. Sarcoma Patients
The patients, who were aged 5 to 10 years, had significantly lower mortality than the patients aged 1 to 5 years (0.30 (0.14, 0.63), P = 0.001). History of parental relation was significantly associated with higher mortality risk (Table 1). Patient treatment including chemotherapy and surgery and radiotherapy significantly decreased the risk of mortality (0.28 (0.11, 0.69), P = 0.006). Experience of metastasis was associated with a higher risk of death (3.80 (2.16, 6.69), P < 0.001).
5. Discussion
The survival rate of children with cancer was affected by many factors such as the type, level, and histology of the child's cancer, age, gender and race, and his/her primary health condition and access to health care, insurance coverage, and follow-up after initial treatment. This study determined the importance of survival-related factors (12, 13).
In this study, the death risk from leukemia for children with the age under 1 year old was 7.6 times higher than the children older than 1 year old. Other studies revealed that the 5-year survival rate of children's leukemia has significantly increased by 83.7% from 1990 to 1994 and by 90.4% from 2000 to 2005 in all age groups except infants under 1 year old (14) and with aging, the survival rate of children with cancer increases (15, 16).
Proper cancer treatment is an important determining factor in the long-term survival of children after infection. Due to the aggressive nature of most pediatric cancers, the use of combination therapies, variety in using chemotherapy drugs, the addition of radiotherapy, and other alternative therapies such as immunotherapy to the treatment process in most pediatric cancers can increase the survival of infected children (17).
According to the results of this study, combination therapy more than chemotherapy increases the survival time itself, and studies over time show that with the advancement of treatment techniques and the addition of treatment approaches, the survival of children with cancer has increased over time (14, 18, 19). On the other hand, an important point to consider is the long-term effects of more aggressive treatment in these children (20, 21).
Advances in pediatric oncology have not only improved survival but also reduced the long-term effects of the disease by adopting a risk-based treatment approach (22). This approach has led to a change in treatment and care standards for fatal pediatric cancers, including nervous system tumors, leukemia, and sarcoma. The risk-adjusted approach allows treatment to be intensified in the high-risk group, while in the low-risk group, the toxicity deficiency and delay (tardive) effects can be minimized without compromising survival (23).
According to the results of this study, local recurrence of cancer metastasis is one of the risk factors with a high-risk ratio in reducing patient survival in these cancers. Recurrence is still the leading cause of failure in acute myeloid leukemia in children (24). In the study of Teachey and Hunger, cancer recurrence in children with ALL has improved greatly due to a more accurate classification of risk, intensification of treatment, and a better understanding of the whole biology (25).
Also, patients with leukemia and sarcoma who had a familial relationship had a higher death risk ratio than patients, who did not have a familial relationship. A wide variety of cancers in children are familial (26).
It is well established that genetic components are involved in increasing the risk of developing leukemia. For this reason, the familial relationship of parents increases the children's homozygosity and increases the risk of cancer (27). Mehrvar et al. reported that 41% of parents of children with leukemia had a familial relationship (28) and Bener et al.’s study showed the rate of leukemia and lymphoma in children of parents with a familial relationship was higher than in the unrelated group (29).
It is important to have periodic and regular care of children with family risks, such as familial relationships of parents or a family history of cancer for early diagnosis and initiation of life-saving treatments. Also, genetic counseling in families with genome-related cancers today is promising for identifying the family cancer genome and taking further care towards practical implications (30, 31).
Mahak Hospital is a cancer center with patient admissions from all over Iran. And the results of this study can probably be generalized to Iranian children.
The study was limited in the number of non-Iranians compared to Iranians and the outcome in patients because in some cases, the outcome was not clear and we had to call again.
Survival analysis using a parametric approach, which is used for data analysis in this study, could be a strong point because these models result in a more precise estimation than the semi-parametric models if the function was selected appropriately (31). In addition, all the possible parametric models were fitted to the data and, then, the Gompertz model as the better fit was finally chosen. It is suggested that other cancers be studied by parametric model fitness in future studies (32, 33).
5.1. Conclusions
The most important factors affecting the survival of children with common cancers of leukemia, retinoblastoma, brain tumors, and sarcoma were age > 1 year for leukemia, 5 to 10 years for sarcoma, parental familial relationships (sarcoma and leukemia), combination therapy (leukemia, retinoblastoma, and sarcoma), and local recurrence and metastasis of primary cancer using Gompertz model. Further studies on the possibility of designing and implementing periodic care in children with risk factors for cancer are needed.
Acknowledgements
References
-
1.
Arbyn M, Weiderpass E, Bruni L, de Sanjose S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8(2):e191-203. [PubMed ID: 31812369]. [PubMed Central ID: PMC7025157]. https://doi.org/10.1016/S2214-109X(19)30482-6.
-
2.
Rodriguez-Galindo C, Friedrich P, Alcasabas P, Antillon F, Banavali S, Castillo L, et al. Toward the Cure of All Children With Cancer Through Collaborative Efforts: Pediatric Oncology As a Global Challenge. J Clin Oncol. 2015;33(27):3065-73. [PubMed ID: 26304881]. [PubMed Central ID: PMC4979198]. https://doi.org/10.1200/JCO.2014.60.6376.
-
3.
Yang L, Fujimoto J, Qiu D, Sakamoto N. Childhood cancer in Japan: focusing on trend in mortality from 1970 to 2006. Ann Oncol. 2009;20(1):166-74. [PubMed ID: 18718890]. https://doi.org/10.1093/annonc/mdn562.
-
4.
Khazaei S, Ayubi E, Soheylizad M, Manosri K. Incidence rate and distribution of common cancers among Iranian children. Middle East J Cancer. 2017;8(1):39-42.
-
5.
Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56(2):106-30. [PubMed ID: 16514137]. https://doi.org/10.3322/canjclin.56.2.106.
-
6.
Bhakta N, Force LM, Allemani C, Atun R, Bray F, Coleman MP, et al. Childhood cancer burden: a review of global estimates. Lancet Oncol. 2019;20(1):e42-53. [PubMed ID: 30614477]. https://doi.org/10.1016/S1470-2045(18)30761-7.
-
7.
Mousavi SM, Pourfeizi A, Dastgiri S. Childhood cancer in Iran. J Pediatr Hematol Oncol. 2010;32(5):376-82. [PubMed ID: 20588194]. https://doi.org/10.1097/MPH.0b013e3181e003f7.
-
8.
Keramatinia A, Mohseny M, Akbari ME, Mosavi-Jarrahi A, Monfared ED, Amanpour F, et al. Determinants of survival of common childhood cancers in Iran. J Res Med Sci. 2018;23:101. [PubMed ID: 30595709]. [PubMed Central ID: PMC6282777]. https://doi.org/10.4103/jrms.JRMS_835_17.
-
9.
Stack M, Walsh PM, Comber H, Ryan CA, O'Lorcain P. Childhood cancer in Ireland: a population-based study. Arch Dis Child. 2007;92(10):890-7. [PubMed ID: 17566053]. [PubMed Central ID: PMC2083220]. https://doi.org/10.1136/adc.2005.087544.
-
10.
Kleinbaum DG, Klein M. Survival Analysis: A Self-Learning Text. 3. Berlin/Heidelberg, Germany: Springer; 2010.
-
11.
Kleinbaum DG, Dietz K, Gail M, Klein M. Logistic regression. Springer; 2002.
-
12.
Michel G, von der Weid NX, Zwahlen M, Redmond S, Strippoli MP, Kuehni CE, et al. Incidence of childhood cancer in Switzerland: the Swiss Childhood Cancer Registry. Pediatr Blood Cancer. 2008;50(1):46-51. [PubMed ID: 17226849]. https://doi.org/10.1002/pbc.21129.
-
13.
Ferrari A, Lo Vullo S, Giardiello D, Veneroni L, Magni C, Clerici CA, et al. The Sooner the Better? How Symptom Interval Correlates With Outcome in Children and Adolescents With Solid Tumors: Regression Tree Analysis of the Findings of a Prospective Study. Pediatr Blood Cancer. 2016;63(3):479-85. [PubMed ID: 26797893]. https://doi.org/10.1002/pbc.25833.
-
14.
Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. J Clin Oncol. 2012;30(14):1663-9. [PubMed ID: 22412151]. [PubMed Central ID: PMC3383113]. https://doi.org/10.1200/JCO.2011.37.8018.
-
15.
Ljungman G, Jakobson A, Behrendtz M, Ek T, Friberg LG, Hjalmars U, et al. Incidence and survival analyses in children with solid tumours diagnosed in Sweden between 1983 and 2007. Acta Paediatr. 2011;100(5):750-7. [PubMed ID: 21158910]. https://doi.org/10.1111/j.1651-2227.2010.02122.x.
-
16.
Kaatsch P. Epidemiology of childhood cancer. Cancer Treat Rev. 2010;36(4):277-85. [PubMed ID: 20231056]. https://doi.org/10.1016/j.ctrv.2010.02.003.
-
17.
Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271-89. [PubMed ID: 27253694]. https://doi.org/10.3322/caac.21349.
-
18.
Gatta G, Botta L, Rossi S, Aareleid T, Bielska-Lasota M, Clavel J, et al. Childhood cancer survival in Europe 1999-2007: results of EUROCARE-5--a population-based study. Lancet Oncol. 2014;15(1):35-47. [PubMed ID: 24314616]. https://doi.org/10.1016/S1470-2045(13)70548-5.
-
19.
Loeffler M, Brosteanu O, Hasenclever D, Sextro M, Assouline D, Bartolucci AA, et al. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol. 1998;16(3):818-29. [PubMed ID: 9508162]. https://doi.org/10.1200/JCO.1998.16.3.818.
-
20.
Nurgali K, Jagoe RT, Abalo R. Editorial: Adverse Effects of Cancer Chemotherapy: Anything New to Improve Tolerance and Reduce Sequelae? Front Pharmacol. 2018;9:245. [PubMed ID: 29623040]. [PubMed Central ID: PMC5874321]. https://doi.org/10.3389/fphar.2018.00245.
-
21.
Turcotte LM, Neglia JP, Reulen RC, Ronckers CM, van Leeuwen FE, Morton LM, et al. Risk, Risk Factors, and Surveillance of Subsequent Malignant Neoplasms in Survivors of Childhood Cancer: A Review. J Clin Oncol. 2018;36(21):2145-52. [PubMed ID: 29874133]. [PubMed Central ID: PMC6075849]. https://doi.org/10.1200/JCO.2017.76.7764.
-
22.
Spinner MA, Advani RH. Risk-adapted therapy for advanced-stage Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2018;2018(1):200-6. [PubMed ID: 30504311]. [PubMed Central ID: PMC6245987]. https://doi.org/10.1182/asheducation-2018.1.200.
-
23.
Saletta F, Seng MS, Lau LM. Advances in paediatric cancer treatment. Transl Pediatr. 2014;3(2):156-82. [PubMed ID: 26835334]. [PubMed Central ID: PMC4729100]. https://doi.org/10.3978/j.issn.2224-4336.2014.02.01.
-
24.
Sander A, Zimmermann M, Dworzak M, Fleischhack G, von Neuhoff C, Reinhardt D, et al. Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials. Leukemia. 2010;24(8):1422-8. [PubMed ID: 20535146]. https://doi.org/10.1038/leu.2010.127.
-
25.
Teachey DT, Hunger SP. Predicting relapse risk in childhood acute lymphoblastic leukaemia. Br J Haematol. 2013;162(5):606-20. [PubMed ID: 23808872]. https://doi.org/10.1111/bjh.12442.
-
26.
Strahm B, Malkin D. Hereditary cancer predisposition in children: genetic basis and clinical implications. Int J Cancer. 2006;119(9):2001-6. [PubMed ID: 16642469]. https://doi.org/10.1002/ijc.21962.
-
27.
Saadat M. Age-standardized Incidence Rates for Leukemia Associated with Consanguineous Marriages in 68 Countries, an Ecological Study. Mediterr J Hematol Infect Dis. 2015;7(1). e2015027. [PubMed ID: 25960855]. [PubMed Central ID: PMC4418370]. https://doi.org/10.4084/MJHID.2015.027.
-
28.
Mehrvar A, Faranoush M, Hedayati Asl AA, Tashvighi M, Fazeli MA, Mehrvar N, et al. Epidemiological Features of Childhood Acute Leukemia at MAHAK’s Pediatric Cancer Treatment and Research Center (MPCTRC), Tehran, Iran. Basic Clin Cancer Res. 2015;7(1):9-15.
-
29.
Bener A, El Ayoubi HR, Chouchane L, Ali AI, Al-Kubaisi A, Al-Sulaiti H, et al. Impact of consanguinity on cancer in a highly endogamous population. Asian Pac J Cancer Prev. 2009;10(1):35-40. [PubMed ID: 19469621].
-
30.
Augustine P. Cancer in Developing Countries - Concerns. Kerala Medical Journal. 2019;12(1):27-8.
-
31.
Jeong J. A new parametric family for modelling cumulative incidence functions: application to breast cancer data. J R Stat Soc Ser A. 2006;169(2):289-303. https://doi.org/10.1111/j.1467-985X.2006.00409.x.
-
32.
Emamalizadeh B, Jamshidi J, Movafagh A, Ohadi M, Khaniani MS, Kazeminasab S, et al. RIT2 Polymorphisms: Is There a Differential Association? Mol Neurobiol. 2017;54(3):2234-40. [PubMed ID: 26941103]. https://doi.org/10.1007/s12035-016-9815-4.
-
33.
Mashhoudi Barez M, Tajziehchi M, Heidari MH, Bushehri A, Moayer F, Mansouri N, et al. Stimulation Effect of Low Level Laser Therapy on Sciatic Nerve Regeneration in Rat. J Lasers Med Sci. 2017;8(Suppl 1):S32-7. [PubMed ID: 29071033]. [PubMed Central ID: PMC5642176]. https://doi.org/10.15171/jlms.2017.s7.